Literature DB >> 8762873

Immunohistochemical expression of Epstein-Barr virus-encoded latent membrane protein (LMP-1) in paraffin sections of EBV-associated nasopharyngeal carcinoma in Spanish patients.

F J Vera-Sempere1, J S Burgos, M S Botella, J Cordoba, M Gobernado.   

Abstract

Nasopharyngeal carcinoma (NPC) paraffin samples, from Spanish patients, of distinct histological types, including squamous cell carcinoma (10 cases), nonkeratinising carcinoma (12 cases) and undifferentiated carcinoma (29 cases) were analysed for Epstein-Barr virus (EBV) detection and EBV-encoded latent membrane protein (LMP-1) expression using a sensitive nested-polymerase chain reaction with four oligonucleotide primers specific for EBV genome (EB-1, 2, 3, 4) and immunohistochemistry by means of CS1-4 pool monoclonal antibody. EBV genome was detected regardless of histological type in 100% of samples with sufficient DNA quality to permit viral diagnosis (50 out of 51 cases), supporting the previous view that all types of NPC are variants of an EBV-associated malignancy. However LMP-1, an EBV-encoded oncogenic protein, was detected in 40 out of 51 samples (78.4%) and LMP-1 immunohistochemical expression was not apparently influenced by histological type, primary or metastatic site, clinical stage, age or sex. This high percentage of detection of LMP-1 in our cases supports a role for EBV in the pathogenesis of different types of NPC, but the lack of constant expression of LMP-1 in NPC remains unclear and various reasons are postulated to explain the absence of this oncogenic protein in some EBV-associated NPCs.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8762873     DOI: 10.1016/0964-1955(95)00093-3

Source DB:  PubMed          Journal:  Eur J Cancer B Oral Oncol        ISSN: 0964-1955


  12 in total

1.  Morphometric study of tumor angiogenesis as a new prognostic factor in nasopharyngeal carcinoma patients.

Authors:  L Rubio; J S Burgos; C Morera; F J Vera-Sempere
Journal:  Pathol Oncol Res       Date:  2000       Impact factor: 3.201

2.  Assessment of Epstein-Barr virus in blood from patients with multiple sclerosis.

Authors:  Gloudina M Hon; Mogamat S Hassan; Susan J van Rensburg; Rajiv T Erasmus; Tandi E Matsha
Journal:  Metab Brain Dis       Date:  2012-03-10       Impact factor: 3.584

Review 3.  Involvement of the Epstein-Barr virus in the nasopharyngeal carcinoma pathogenesis.

Authors:  Javier S Burgos
Journal:  Med Oncol       Date:  2005       Impact factor: 3.064

4.  Immunohistochemical expression of latent membrane protein 1 (LMP1) and p53 in nasopharyngeal carcinoma: Moroccan experience.

Authors:  I Tabyaoui; Z Serhier; S Sahraoui; S Sayd; R Cadi; O M Bennani; A Benider; S Zamiati; Jouti N Tahiri
Journal:  Afr Health Sci       Date:  2013-09       Impact factor: 0.927

Review 5.  Epstein-Barr virus antibodies and the risk of associated malignancies: review of the literature.

Authors:  Anna E Coghill; Allan Hildesheim
Journal:  Am J Epidemiol       Date:  2014-08-28       Impact factor: 4.897

6.  Absence of p53 alterations in nasopharyngeal carcinoma Spanish patients with Epstein-Barr virus infection.

Authors:  Javier S Burgos
Journal:  Virus Genes       Date:  2003-12       Impact factor: 2.332

7.  Expression of EBV encoded viral RNA 1, 2 and anti-inflammatory cytokine (interleukin-10) in FFPE lymphoma specimens: a preliminary study for diagnostic implication in Pakistan.

Authors:  Taimoor I Sheikh; Ishtiaq Qadri
Journal:  Diagn Pathol       Date:  2011-07-27       Impact factor: 2.644

8.  Epstein-Barr virus Latent Membrane Protein LMP1 reduces p53 protein levels independent of the PI3K-Akt pathway.

Authors:  Roslina Husaini; Munirah Ahmad; Alan Soo-Beng Khoo
Journal:  BMC Res Notes       Date:  2011-12-21

9.  Epstein-Barr virus latent membrane protein-1 (LMP-1) 30-bp deletion and Xho I-loss is associated with type III nasopharyngeal carcinoma in Malaysia.

Authors:  Hui Shien See; Yoke Yeow Yap; Wai Kien Yip; Heng Fong Seow
Journal:  World J Surg Oncol       Date:  2008-02-15       Impact factor: 2.754

10.  ATR activated by EB virus facilitates chemotherapy resistance to cisplatin or 5-fluorouracil in human nasopharyngeal carcinoma.

Authors:  Bo Zhang; Bomiao Cui; Jintao Du; Xin Shen; Kun Wang; Jiao Chen; Liying Xiao; Chongkui Sun; Yan Li
Journal:  Cancer Manag Res       Date:  2019-01-09       Impact factor: 3.989

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.